On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.

ABSTRACT:

Background

Neoadjuvant chemotherapy is increasingly given preoperatively to shrink breast tumours prior to surgery. This approach also provides the opportunity to study the molecular changes associated with treatment and evaluate whether on-treatment sequential samples can improve response and outcome predictions over diagnostic or excision samples alone.

Methods

This study included a total of 97 samples from a cohort of 50 women (aged 29-76, with 46% ER+ and 20% HER2+ tumours) with primary operable breast cancer who had been treated with neoadjuvant chemotherapy. Biopsies were taken at diagnosis, at 2 weeks on-treatment, mid-chemotherapy, and at resection. Fresh frozen samples were sequenced with Ion AmpliSeq Transcriptome yielding expression values for 12,635 genes. Differ

SUBMITTER: Bownes RJ 

PROVIDER: S-EPMC6570893 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature